Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMO6P0)

Drug Name

Tifacogin Drug Info

Synonyms

LACI; SC-59735; TFP-561; LACI, Pharmacia/Chiron; LACI, Searle/Chiron; Lipoprotein associated coagulation inhibitor, Pharmacia/Chiron;Lipoprotein associated coagulation inhibitor, Searle/Chiron; RTFPI, Pharmacia/Chiron; RTFPI, Searle/Chiron; Tissue factor pathway inhibitor, Pharmacia/Chiron; Tissue factor pathway inhibitor, Searle/Chiron

Indication

Disease Entry	ICD 11	Status	REF
Sepsis	1G40-1G41	Phase 3	[1]

Cross-matching ID

PubChem CID: 961320
CAS Number: CAS 73325-61-8
TTD Drug ID: DMMO6P0

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tissue factor pathway inhibitor (TFPI)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PF-06741086	DMW63TQ	Hemophilia	3B10.0	Phase 3	[2]
Concizumab	DM1BRWD	Haemophilia A	3B10.0	Phase 3	[3]
NN-7415	DMHVIZC	Factor IX deficiency	3B11	Phase 1	[4]
BAX-499	DM3415L	Factor IX deficiency	3B11	Phase 1	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tissue factor pathway inhibitor (TFPI)	TT068JH	TFPI1_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
2	Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody. AAPS J. 2019 Mar 29;21(3):46.
3	Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982.
4	Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.J Thromb Haemost.2015 May;13(5):743-54.
5	Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein. J Thromb Haemost. 2013 Jun;11(6):1137-45.